Fundraising Fox
🦊/Companies
Sign in

Cleave Biosciences

Burlingame, US · Delaware corporation · 8 known investors

Find your way into Cleave Biosciences

Biotech

Founders & leadership

MR
Mark RolfeExecutive
LSLaura Shawver
Laura ShawverinCEO2011–2019Executive Officer, Director at Capstan Therapeutics
TS
Timothy SmithExecutive

Board

ASAlfred Scheidegger
Alfred Scheideggerin𝕏Board directorManaging Partner at Nextech Invest
PTPeter Thompson
Peter ThompsoninCo-Founder, DirectorGeneral Partner at OrbiMed
CGCarol Gallagher
Carol Gallagherin𝕏Board directorAdvisor at New Enterprise Associates (NEA)
JRJonathan Root
Jonathan RootinBoard directorGeneral Partner at US Venture Partners
AS
Andrew SchwabBoard director
DH
Dennis HennerBoard directorGeneral Partner at Clarus Ventures
LS
Lewis ShusterBoard director

Investors · 8

Astellas Venture Management LLCSouth San Francisco · $200K – $5M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Nextech InvestZurich · $648K – $3.2Mvia Alfred Scheidegger · board
5AM VenturesreportedBoston · $100K – $4M
Clarus VenturesreportedMenlo Park
OrbiMedreportedNew York · $1M – $75M
Osage University PartnersreportedBala Cynwyd
US Venture PartnersreportedMenlo Park · $500K – $10M

Reported raises · per SEC filings

Form D private placements

$37.9M disclosed across 2 of 3 rounds · 2016–2025

▶$12MraisedJun 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amy BurroughsExecutive Officer, Director
  • Laura ShawverDirector
  • Jonathan RootDirector
  • Andrew SchwabDirector
  • Peter ThompsonDirector
Offering amount
$20.8M
Amount sold
$12M
First sale
Jun 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26MraisedAug 2016 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alfred ScheideggerDirector
  • Mark RolfeExecutive Officer
  • Peter ThompsonDirector
  • Laura ShawverExecutive Officer, Director
  • Lewis ShusterDirector
  • Carol GallagherDirector
  • Jonathan RootDirector
  • Timothy SmithExecutive Officer
  • Andrew SchwabDirector
  • Dennis HennerDirector
Offering amount
$36.8M
Amount sold
$26M
First sale
Jun 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Cleave Biosciences went on to found or lead other companies.

Peter ThompsonCo-Founder, DirectorFounded Silverback Therapeutics +3Peter Thompson, M.D.Co-Founder, DirectorFounded Silverback Therapeutics +3

In the news

Cleave Biosciences Gets $42M In VC Funding | Institutional Investorinv-dev.institutionalinvestor.com · Dec 2025Cleave Therapeutics, Inc. announced that it expects to receive $5.5 million in funding from CASI Pharmaceuticals, Inc. | MarketScreenermarketscreener.com · Mar 2021Cleave Biosciences cuts to series B with $37m -globalventuring.com · Aug 2016Bay Area's Cleave Biosciences Rakes in $37 Million With Help From New Investor Celgene - BioSpacebiospace.com · Aug 2016Cleave Biosciences Raises $37 Million Series B Financingprnewswire.com · Aug 2016Cleave Biosciences Adds New Investor and $10 Million to Series A Financingprnewswire.com · Apr 2013

Frequently asked questions

Who are Cleave Biosciences's investors?
Cleave Biosciences's investors include Astellas Venture Management LLC, New Enterprise Associates (NEA), Nextech Invest, 5AM Ventures, Clarus Ventures, OrbiMed, Osage University Partners, US Venture Partners.
How much funding has Cleave Biosciences raised?
Cleave Biosciences has disclosed $37.9M raised across 2 of its 3 known rounds.
Where is Cleave Biosciences headquartered?
Cleave Biosciences is headquartered in Burlingame, US.